You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-L1 imaging

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Head Neck Cancer Trial in Netherlands (PD-L1 imaging, Durvalumab)

Completed
  • Head and Neck Cancer
  • Amsterdam, Netherlands
  • +3 more
Jan 6, 2022

Advanced Non Small Cell Lung Cancer Trial ([18F]F-AraG)

Not yet recruiting
  • Advanced Non Small Cell Lung Cancer
  • (no location specified)
Oct 24, 2023

Non Small Cell Lung Cancer Trial in Nijmegen (89Zr-avelumab PET, Avelumab)

Completed
  • Non Small Cell Lung Cancer
  • Nijmegen, Netherlands
    Radboud University
Jan 6, 2022

Molecular PD-L1 PET/CT Imaging With 89Zr-atezolizumab in

Not yet recruiting
  • Metastatic Triple-Negative Breast Carcinoma
  • 89Zr-atezolizumab PET/CT
  • (no location specified)
Feb 22, 2023

Esophageal Cancer Trial in Groningen (Fluorescence endoscopy using durvalumab-680LT)

Not yet recruiting
  • Esophageal Cancer
  • Fluorescence endoscopy using durvalumab-680LT
  • Groningen, Netherlands
    University Medical Center Groningen
Jul 4, 2022

Gastrointestinal Tumors Trial in Beijing (68Ga-WL12 PET/CT)

Recruiting
  • Gastrointestinal Tumors
  • 68Ga-WL12 PET/CT
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Jul 18, 2022

Solid Tumor, Lung Cancer Trial in Beijing (18F-WL12 PET or 68Ga-WL12 PET)

Recruiting
  • Solid Tumor
  • Lung Cancer
  • 18F-WL12 PET or 68Ga-WL12 PET
  • Beijing, China
    Shunlian Zhou
Jul 18, 2022

Head and Neck Squamous Cell Carcinoma, Magnetic Resonance Imaging, Neoadjuvant Therapy Trial in Guangzhou

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +2 more
    • Guangzhou, Guangdong, China
      Sun Yat-sen Memorial Hospital
    Jul 27, 2023

    Large B-cell Lymphoma Trial in Groningen (89Zr-atezolizumab PET-imaging)

    Recruiting
    • Large B-cell Lymphoma
    • 89Zr-atezolizumab PET-imaging
    • Groningen, Netherlands
      University Medical Center Groningen
    Jul 15, 2022

    Metastatic Oropharyngeal Carcinoma, Recurrent Oropharyngeal Carcinoma Trial in Nashville (DNA Vaccine, Human Papillomavirus

    Not yet recruiting
    • Metastatic Oropharyngeal Carcinoma
    • Recurrent Oropharyngeal Carcinoma
    • DNA Vaccine
    • +6 more
    • Nashville, Tennessee
      Vanderbilt University/Ingram Cancer Center
    Mar 22, 2023

    Advanced PD-L1 Positive Malignancies Trial in New York (89Zr?DFO?REGN3504)

    Terminated
    • Advanced PD-L1 Positive Malignancies
    • New York, New York
    • +1 more
    Feb 7, 2022

    Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell

    Not yet recruiting
    • Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
    • +2 more
    • Biopsy
    • +6 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Sep 28, 2023

    Lung Cancer, Melanoma, PD-L1 Trial in Beijing (68Ga-THP-APN09)

    Recruiting
    • Lung Cancer
    • +3 more
    • 68Ga-THP-APN09
    • Beijing, Beijing, China
      Beijing cancer hospital
    Dec 12, 2021

    Rectal Cancer Stage, Oesophageal Cancer Trial in Vienna (CRT, SCPRT, CROSS Protocol)

    Not yet recruiting
    • Rectal Cancer Stage
    • Oesophageal Cancer
    • CRT
    • +3 more
    • Vienna, Austria
      Medical University of Vienna
    Mar 26, 2022

    Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Tumor in the Brain, Stage IV Lung Cancer AJCC v8 Trial in Duarte

    Not yet recruiting
    • Metastatic Lung Non-Small Cell Carcinoma
    • +2 more
    • Biospecimen Collection
    • +4 more
    • Duarte, California
      City of Hope Medical Center
    May 1, 2023

    TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular

    Recruiting
    • Hepatocellular Carcinoma
      • Nanjing, Jiangsu, China
        Zhongda Hospital, Southeast University
      Mar 4, 2022

      Solid Tumor, Adult Trial in Wuxi (89Zr-KN035)

      Recruiting
      • Solid Tumor, Adult
      • Wuxi, Jiangsu, China
        Wuxi No. 4 People's Hospital
      Jul 20, 2021

      NSCLC (NSCLC) Trial in Baltimore ([18F]F-AraG Injection)

      Recruiting
      • Non-small Cell Lung Cancer (NSCLC)
      • [18F]F-AraG Injection
      • Baltimore, Maryland
        Johns Hopkins University
      Dec 14, 2021

      Melanoma Trial in Groningen (PD-L1 PET imaging)

      Completed
      • Melanoma
      • PD-L1 PET imaging
      • Groningen, Netherlands
        UMCG
      Apr 26, 2021

      Non Small Cell Lung Cancer Trial in Palo Alto, Sacramento, Stony Brook ([18F]F AraG)

      Recruiting
      • Non Small Cell Lung Cancer
      • [18F]F AraG
      • Palo Alto, California
      • +2 more
      Apr 11, 2022

      Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8 Trial (Fluorine

      Withdrawn
      • Advanced Lung Non-Small Cell Carcinoma
      • +8 more
      • Fluorine F 18 Ara-G
      • (no location specified)
      Jan 24, 2022

      Advanced Solid Tumor Trial in Amsterdam, Groningen (89Zr-S095012 tracer and S095012 will be administered via an IV infusion)

      Recruiting
      • Advanced Solid Tumor
      • 89Zr-S095012 tracer and S095012 will be administered via an IV infusion
      • Amsterdam, Netherlands
      • +1 more
      Dec 9, 2022

      Locally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 Expression Trial in Groningen (89Zr-MPDL-3280A-PET scans)

      Active, not recruiting
      • Locally Advanced or Metastatic Solid Tumors Irrespective of PD-L1 Expression
      • 89Zr-MPDL-3280A-PET scans
      • Groningen, Netherlands
        University Medical Center Groningen
      Feb 28, 2022

      Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Locally Advanced Merkel Cell

      Not yet recruiting
      • Clinical Stage III Merkel Cell Carcinoma AJCC v8
      • +5 more
      • (no location specified)
      Jul 13, 2023

      Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

      Completed
      • Advanced Solid Tumor
      • Inosine 0.2g orally 3 times/day
      • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
      • Beijing, Beijing, China
        Qin li
      Mar 30, 2023